Science1 publisherNot yet confirmed elsewhere2 min readPublished
Stanford molecule makes a lymphoma driver switch on cancer cells' own death genes
Stanford Medicine built a two-part molecule that turns a lymphoma-driving protein against the cancer cells it drives, clearing tumors in mice within 11 days. It switches on the cells' built-in death genes, and has not yet been tested in people.
The Scientist · Science desk
What happened
- BCL6, the protein the molecule targets, drives diffuse large B-cell lymphoma, the most common form of non-Hodgkin lymphoma and a type of blood cancer.
- In lymphoma cells BCL6 jams in the on position, continually silencing the genes that would kill the cell and letting the malignant cells keep dividing.
- The study was published in the journal Cell by researchers at Stanford Medicine and the MD Anderson Cancer Center.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- capability A protein the cancer cannot survive without becomes the trigger for its own death, so the molecule reaches the cells precisely because they depend on BCL6.
- precedent If the two-sided design generalizes, it offers a way to turn other disease-driving proteins against the cells that rely on them, beyond this one lymphoma.
- constraint The clearance came from mice carrying human lymphoma cells on twice-daily dosing, so it shows the mechanism works in an animal, not that a patient could tolerate the compound or stay in remission.
The molecule, TCIP3, is built like a two-sided key. [14] "One side binds to BCL6," said Meredith Nix, a graduate student and co-lead author of the study. [8] "The other side binds either of two proteins called P300 and CBP that add chemical tags called acetyl marks onto nearby proteins." [15] Dragged into contact with BCL6, those enzymes tag it. The tag strips its ability to repress the death genes downstream. [16] They also tag the histones that package the DNA, loosening their grip so the transcription factors that switch genes on can reach them. [17] The method, chemically induced proximity, forces together two proteins that in the cell meet only rarely, if at all. [13]
That works differently from the BCL6 drugs already in use, which block or degrade the protein. [18] Nix put the difference this way: "We're not just relieving the repression conferred by BCL6; we're also actively driving the expression of these cell death genes, which is why we're able to get really potent compounds." [19] She compared it to easing off a car's brake versus flooring the accelerator. [21]
BCL6 is the target because the cancer depends on it. [2] In a healthy immune cell the protein binds DNA and temporarily silences the genes that would halt growth or start cell death. [10] That pause gives the cell time to multiply during an immune response. [10] Once the threat passes, other proteins modify BCL6 and the surplus cells die by apoptosis. [11]
The strategy has been in development in the lab for years. [20] Gerald Crabtree, who shares senior authorship, described the aim: "We're trying to essentially fight cancer with its cause -- taking the driving force of the cancer and then rewiring it to activate cell death mechanisms." [4] [5]
What to watch
- Whether the compound clears tumors without toxicity in larger animals, and at what dose, before any human trial.
- Whether TCIP3 or a related proximity molecule is tried against the other cancers and autoimmune diseases the team names.
- Whether the tumors return after dosing stops, which the 11-day mouse window does not address.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence40
- Adoption
- Insufficient
- Hype gap+25
- Incentives45
- Confidence40
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
In mice, twice-daily treatment with the experimental compound caused aggressive human lymphoma tumors to disappear within 11 days.
- [2]
Stanford Medicine researchers developed a two-part molecule that turns a major driver of B-cell lymphoma against the cancer cells that depend on it.
- [3]
Instead of simply shutting down the cancer-promoting protein, the molecule connects it to another protein capable of activating the cell's built-in death program.
- [4]
"We're trying to essentially fight cancer with its cause -- taking the driving force of the cancer and then rewiring it to activate cell death mechanisms."
- [5]
Gerald Crabtree, MD, is the David Korn Professor in Pathology and a professor of developmental biology, and shares senior authorship of the study.
- [7]
Senior authorship is shared by Gerald Crabtree, Nathanael Gray and Stephen Hinshaw of Stanford, and Michael Green of the MD Anderson Cancer Center.
- [8]
Graduate student Meredith Nix and postdoctoral scholar Sai Gourisankar, PhD, are the lead authors of the research.
- [9]
Diffuse large B-cell lymphoma is the most common form of non-Hodgkin lymphoma, a type of blood cancer, and in many cases is driven by the protein BCL6.
- [10]
In healthy immune cells, BCL6 attaches to DNA and temporarily shuts down genes that would normally stop cell growth or initiate cell death, giving immune cells time to multiply during an immune response.
- [11]
Once the immune threat has passed, other proteins modify BCL6 so it can no longer silence those genes, and the excess immune cells die through apoptosis.
- [12]
In lymphoma cells, BCL6 can stay stuck in the on position, continually suppressing death-related genes and allowing malignant cells to keep multiplying.
- [13]
The team used a technique known as chemically induced proximity, which uses chemical connections to bring together molecules that normally interact only rarely, if at all.
- [14]
The researchers created a molecule called TCIP3 that functions somewhat like a two-sided key.
- [15]
"One side binds to BCL6. The other side binds either of two proteins called P300 and CBP that add chemical tags called acetyl marks onto nearby proteins."
- [16]
When an acetyl tag is added to BCL6, the protein loses its ability to suppress the cell-death genes downstream from it.
- [17]
P300 and CBP also place acetyl tags on nearby histones, loosening their grip on DNA and opening access for the transcription factors needed to turn genes on.
- [18]
This produces a different effect from existing drugs that target BCL6 by blocking or degrading it.
- [19]
"We're not just relieving the repression conferred by BCL6; we're also actively driving the expression of these cell death genes, which is why we're able to get really potent compounds."
- [20]
The work advances a strategy the research team has been developing for years.
- [21]
Nix compared the difference to easing off a car's brake versus flooring the accelerator.
- [22]
Much more testing is needed before the treatment could reach patients.
- [23]
The researchers believe this type of molecular rewiring could eventually have applications beyond lymphoma, including other cancers and some autoimmune diseases.
Sources
1 independent publisher whose own reporting we read for this story.
- sciencedaily.comStanford scientists turn a cancer driver into a kill switch
1 article · October 7, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.